FDA delays action on Immunomedics agent

Article

Monoclonal antibody developer Immunomedics suffered a blow fromthe Food and Drug Administration last week. The agency's oncologicdrugs advisory committee deferred a decision on the company'sCEA-Scan colorectal cancer imaging agent and recommended thatit

Monoclonal antibody developer Immunomedics suffered a blow fromthe Food and Drug Administration last week. The agency's oncologicdrugs advisory committee deferred a decision on the company'sCEA-Scan colorectal cancer imaging agent and recommended thatit be reviewed by another FDA committee. News of the committee'sdecision caused the Morris Plains, NJ, company's stock to drop26% to $5.75 a share on Oct. 18.

The FDA last year issued Immunomedics a non-approvable letterfor CEA-Scan (SCAN 9/27/95). Immunomedics said it will continueto work with the FDA to receive approval for the agent.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.